PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases.

PDGF and its receptors are involved in a variety of diseases: cancers, atherosclerosis, balloon injury induced restenosis, pulmonary fibrosis and more. In all cases enhanced signaling of the receptor is the hallmark. In some cases, like chronic monomyelocytic leukemia (CMML), the persistent PDGFR signaling is essential for the survival of the cancer cell. These findings induced the research community as well as the pharmaceutical industry to develop agents that block PDGFR signaling. The possible utilization of PDGFR kinase inhibitors as anti-restenosis agents is likely to move ahead of the utilization of these agents to treat human malignancies.

[1]  J. Fletcher,et al.  Various regions within the alpha‐helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant‐cell fibroblastomas , 1998, Genes, chromosomes & cancer.

[2]  J. Bonner,et al.  Regulation of PDGFR-α in rat pulmonary myofibroblasts by staurosporine , 2001 .

[3]  I. Fishbein,et al.  Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-12951 , 2002, Transplantation.

[4]  B. Druker,et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[5]  D. Morgan,et al.  Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. , 1999, The American journal of pathology.

[6]  M. Reidy,et al.  Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Zilberstein,et al.  Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. , 1991, The American journal of physiology.

[8]  J. C. Fox,et al.  Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. , 1998, Journal of vascular surgery.

[9]  R. Rutherford,et al.  Platelet factors stimulate fibroblasts and smooth muscle cells quiescent in plasma serum to proliferate , 1976, The Journal of cell biology.

[10]  P. Ganz,et al.  Cardiac allograft vasculopathy , 2000, Current opinion in cardiology.

[11]  A. Levitzki,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.

[12]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[13]  M. K. Magnússon,et al.  Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. , 2002, Blood.

[14]  G. Golomb,et al.  Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. , 2003, Bioorganic & medicinal chemistry.

[15]  C. Heldin,et al.  Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. , 1997, Biochemistry.

[16]  C. Heldin,et al.  Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. , 1994, Cancer research.

[17]  Keith Abe,et al.  Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. , 2002, Journal of medicinal chemistry.

[18]  I. Fishbein,et al.  PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. , 1998, Circulation.

[19]  Alexander Levitzki,et al.  Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. , 2005, Biomaterials.

[20]  T. Sjöblom,et al.  The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.

[21]  Alexander Levitzki,et al.  Protein tyrosine kinase inhibitors as novel therapeutic agents. , 1999, Pharmacology & therapeutics.

[22]  G. Mcmahon,et al.  Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. , 1996, Journal of medicinal chemistry.

[23]  R. Dolle,et al.  5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. , 1994, Journal of medicinal chemistry.

[24]  M. Reidy,et al.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.

[25]  G. Condorelli,et al.  Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo , 1995, Nature Medicine.

[26]  N. Pryer,et al.  SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.

[27]  W. Stetler-Stevenson,et al.  Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. , 1997, Circulation.

[28]  W. Zhou,et al.  Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. , 1994, Biochemical and biophysical research communications.

[29]  N. Weissman,et al.  A paclitaxel-eluting stent for the prevention of coronary restenosis. , 2003, The New England journal of medicine.

[30]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[31]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[32]  K. Matsuno,et al.  Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives. , 2002, Journal of medicinal chemistry.

[33]  D. George.  Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. , 2003, Advances in experimental medicine and biology.

[34]  Y. Tano,et al.  Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. , 2003, Japanese journal of ophthalmology.

[35]  C. Dunwiddie,et al.  Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. , 1999, Circulation.

[36]  C. Heldin,et al.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.

[37]  K. Matsuno,et al.  Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. , 2001, The Journal of pharmacology and experimental therapeutics.

[38]  H. Nawata,et al.  Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth. , 2000, The Journal of laboratory and clinical medicine.

[39]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[40]  R. Hershberger,et al.  Late infection in cardiac allograft recipients: profiles, incidence, and outcome. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  R. Ross,et al.  The pathogenesis of atherosclerosis (first of two parts). , 1976, The New England journal of medicine.

[42]  W A Denny,et al.  Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. , 1998, Journal of medicinal chemistry.

[43]  J. Leiden,et al.  Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. , 1995, The Journal of clinical investigation.

[44]  Alexander Levitzki,et al.  Protein kinase inhibitors as a therapeutic modality. , 2003, Accounts of chemical research.

[45]  I. Fishbein,et al.  Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. , 1996, Atherosclerosis.

[46]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[47]  M. Bryckaert,et al.  Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins. , 1992, Experimental cell research.